EUCTR2014-005282-78-Outside-EU/EEA进行中（未招募）1 期
A phase IV, randomised, open-label, controlled study to assess the immunogenicity and safety of the diphtheria, tetanus, pertussis and inactivated poliovirus (DPT-IPV) vaccine Squarekids™ when co-administered with GSK Biologicals' oral live attenuated HRV liquid vaccine Rotarix™ in healthy Japanese infants aged 6 - 12 weeks at the time of the first dose of HRV vaccination. - ROTA-079
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 262
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Subjects’ parent(s)/ Legally Acceptable Representative(s) [LAR(s)] who, in the opinion of the investigator can and will comply with the requirements of the protocol.
- •A male or female between, and including, 6 and 12 weeks of age at the time of the first dose of HRV vaccination.
- •Written informed consent obtained from the parent(s)/LAR(s) of the subject prior to performing any study specific procedure.
- •Healthy subjects as established by medical history and clinical examination before entering into the study.
- •Born full-term as per the delivery records.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 262
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Child in care.
- •Use of any investigational or non-registered product other than the study vaccines within 30 days before the first dose of study vaccine, or planned use during the study period.
- •Chronic administration of immunosuppressants or other immune-modifying drugs since birth. For corticosteroids, this will mean prednisone (>= 0.5 mg/kg/day, or equivalent). Inhaled and topical steroids are allowed.
- •Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period.
- •Administration of long-acting immune-modifying drugs at any time during the study period.
- •Planned administration/administration of a vaccine not fore-seen by the study protocol within the period starting 30 days before the first dose of HRV vaccine administration and ending at Visit 7, with the exception of other routinely administered vaccines like PCV, Hib, BCG, hepatitis B, meningococcal vaccine and inactivated influenza vaccines, which are allowed at any time during the study, if administered at sites different from the sites used to administer the DPT-IPV vaccine.
- •Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational vaccine/product.
- •Uncorrected congenital malformation of the gastrointestinal tract that would predispose for Intussusception (IS).
- •History of IS.
- •Family history of congenital or hereditary immunodeficiency.
- •Any confirmed or suspected immunosuppressive or immu-nodeficient condition, based on medical history and physical examination.
- •Major congenital defects or serious chronic illness.
- •Previous vaccination against rotavirus, diphtheria, tetanus, pertussis and/ or poliovirus.
- •Previous confirmed occurrence of RV GE, diphtheria, tetanus, pertussis, and/ or polio disease.
- •GE within 7 days preceding the HRV vaccine administration.
- •History of any reaction or hypersensitivity likely to be exac-erbated by any component of the HRV or DPT-IPV vaccines.
- •Hypersensitivity to latex.
- •History of any neurological disorders or seizures.
- •History of SCID.
- •Acute disease and/or fever at the time of enrollment.
- •- Fever is defined as temperature = 37.5°C /99.5°F on oral, axillary or tympanic setting, or = 38.0°C /100.4°F on rectal setting.
- •- Subjects with a minor illness without fever may be enrolled at the discretion of the investigator.
研究者
相似试验
进行中（未招募）
1 期
A phase IV, randomized, open-label, controlled, post-licensure study to evaluate the safety of GlaxoSmithKline Biologicals’ HPV-16/18 L1 VLP AS04 vaccine (Cervarix®) when administered intramuscularly according to a 0, 1, 6-month schedule in females aged 18-25 years. - EPI-HPV-111103o medical condition will be investigated in this study. The study will follow vaccinated females and collect safety data focussing on autoimmune diseases, pregnancy outcomes and SAEs considered to be related to the vaccine.EUCTR2007-006651-39-GBGlaxoSmithKline Biologicals100,000
进行中（未招募）
1 期
A Phase IV, open-label, prospective, randomised clinical trial to evaluate the usefulness of measuring nitric oxide in exhaled air in the therapeutic management of adult patients with mild asthmaTreatment in non-smoking adult patients with mild persistent atopic bronchial asthmaMedDRA version: 14.1Level: LLTClassification code 10003555Term: Asthma bronchialSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2012-000372-42-ESFundació per la Recerca i la Docència Sant Joan de Déu
进行中（未招募）
不适用
A phase 4, open label, randomised, controlled study to assess the effect on lipid profile of switching a stable HAART regimen of fixed dose Kivexa + Kaletra to Truvada + Kaletra in adult HIV-1 infected subjects with raised cholesterol - Rocket IIHIV-1 infectionMedDRA version: 9.1Level: LLTClassification code 10020192Term: HIV-1EUCTR2008-002043-16-ITGilead Sciences Europe Ltd160
已完成
4 期
RituxiMab in INDuction therapy for living donor renal transplantatioive donor renal transplantationSurgeryISRCTN95769119Guy's and St Thomas' Hospital NHS Foundation Trust (UK)316
进行中（未招募）
1 期
A randomized, open-label, phase IV monocentric study evaluating the clinical effect of oral immunomodulatory therapy with IMUNOR® in patients with moderate COVID-19 diseaseEUCTR2020-002497-27-CZThomayerova nemocnice30